Compare Crispr Therapeutics AG (CRSP) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Entegris Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Entegris Inc trades at $165.79 (market cap $24.78B). The key difference: Entegris Inc is far larger — about 5.1× Crispr Therapeutics AG's market cap, and Entegris Inc pays a 0.25% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Entegris Inc for 41 Days on average.
| CRSP | ENTG | |
|---|---|---|
Market Cap | $4.88B | $24.78B |
Volume | 2,861,747 | 2,648,320 |
Sector | Health | Technology |
52-Week High | $73.97 | $184.00 |
52-Week Low | $44.34 | $68.80 |
Typical Hold Time | 77 Days | 41 Days |
Enterprise Value | $3.30B | $27.99B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
ENTG trades at $162.19, down 2.48% today, with a bullish technical signal from moving averages. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results expected on October 29, 2026. Revenue for 2025 was $3.20B, with a net income margin of 7.37%. Analyst consensus is strongly bullish, with a price target of $182.43, indicating a 12.5% upside. Recent news highlights strong AI-driven semiconductor demand and institutional buying interest.
The outlook for ENTG is positive, supported by robust earnings performance and growing demand in the semiconductor sector. Key opportunities include expansion in AI-related markets and operational efficiency gains. Risks involve high valuation multiples, competitive pressures, and sensitivity to semiconductor industry cycles. Investors should weigh the strong analyst support against potential market volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
